Please assess the completion status of the following clinical trial:

Trial Title: DAISe 1 Feasibility Study to Evaluate the DAISe Thrombectomy System for Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older.~* Pre-stroke (24 hours prior to stroke onset) independent functional status in activities of daily living with modified Rankin Score 0-1. Patient must be living in their own home, apartment or seniors lodge where no nursing care is required.~* Diagnosis of acute ischemic stroke and referred to interventional neuroradiology center for mechanical thrombectomy with study enrollment time planned within 8 hours from onset of symptoms.~* Disabling stroke defined as a baseline NIHSS \> 6.~* Thrombolytic therapy (IV tPA) received within 4.5 hours of onset/ last known well according to prescribed dosing OR documented ineligibility for thrombolytic therapy.~* Confirmed symptomatic, large vessel occlusion of the intracranial internal carotid artery, middle cerebral artery, M1, or M2 with mTICI 0-1.~* The following baseline imaging criteria should be met: MRI criterion- volume of diffusion restriction visually assessed ≤50 mL OR ASPECTs score 5-10 or T criterion- ASPECTS 6-10 on imaging NE-CT, CTA and/or CTP available~* Signed informed consent from patient or legal representative or if applicable, documented medical necessity for inclusion in a clinical study in an emergency followed by signed informed consent.~* Patient is affiliated in the social security system.~Exclusion Criteria:~* Computed tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of recent/ fresh hemorrhage on presentation.~* Clinical history, past imaging or clinical judgment suggests that the intracranial occlusion is chronic.~* Rapidly improving neurological deficits based on the investigator's clinical judgement.~* Pregnancy; if a woman is of child-bearing potential and urine or serum beta HCG test is positive.~* Severe contrast allergy or absolute contraindication to iodinated contrast.~* Renal failure (serum creatinine level ≥ 3 mg/dL or on dialysis).~* Severe, sustained hypertension resistant to treatment (SBP \>185 mmHg or DBP \>110 mmHg).~* Use of warfarin anticoagulation (or other applicable anti-vitamin k anticoagulants) with International Normalized Ratio (INR) \> 3.0 at the time of the procedure or any known hemorrhagic or coagulation deficiency.~* Use of a direct thrombin inhibitor within the last 48 hours; partial thromboplastin time (PTT) \> 2.0 times the normal prior to procedure.~* Cerebral vasculitis or evidence of active systemic infection.~* Suspicion of aortic dissection, presumed septic embolus or suspicion of bacterial endocarditis.~* Clinical symptoms suggestive of bilateral stroke or occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior/posterior circulation).~* Seizure due to stroke.~* Difficult endovascular access, difficult aortic arch or severe neurovascular tortuosity that will result in an inability to deliver endovascular therapy.~* Evidence of dissection in the carotid or target artery for treatment.~* Presence of a carotid artery stenosis or occlusion requiring balloon angioplasty or stenting at time of the procedure.~* A severe or fatal comorbid illness that will prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient.~* Patient cannot undergo an MRI of the head due to MRI contraindication.~* Patient is unable or unwilling complete follow up visits.~* If before the stroke, the patient is under a legal protective measure, they will not be able to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DAISe Thrombectomy System (Type: EXPERIMENTAL): Mechanical thrombectomy utilizing the DAISe Thrombectomy System, consisting of the DAISe Thrombectomy Device and DAISe Delivery Catheter, used with aspiration.

Based on this trial design, predict the completion outcome and termination type (if applicable).